Potential conflict of interest: Nothing to report.
Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma
Version of Record online: 19 SEP 2013
© 2013 by the American Association for the Study of Liver Diseases
Volume 58, Issue 5, pages 1667–1680, November 2013
How to Cite
Yoshida, S., Kornek, M., Ikenaga, N., Schmelzle, M., Masuzaki, R., Csizmadia, E., Wu, Y., Robson, S. C. and Schuppan, D. (2013), Sublethal heat treatment promotes epithelial-mesenchymal transition and enhances the malignant potential of hepatocellular carcinoma. Hepatology, 58: 1667–1680. doi: 10.1002/hep.26526
This work was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (grant nos.: 1 R21 DK075857-01A2 and U19 AI066313-05; to D.S.) and the German Research Foundation (DFG; grant no.: KO4103/1-1; to M.K.). M.S. also acknowledges grant support from the American Liver Foundation, the DFG (SCHM 2661/1-1 and 2661/1-2), and the German Federal Ministry of Education and Research (BMBF; PtJ-Bio, 0315883).
Some aspects of this study were presented at an oral sessions of Digestive Disease Week 2011 (Abstract no. 896) and at poster sessions of the American Association for the Study of Liver Diseases 2012 (Abstract no. 887) and 2013 (Abstract no. 1804).
- Issue online: 30 OCT 2013
- Version of Record online: 19 SEP 2013
- Accepted manuscript online: 31 MAY 2013 08:42AM EST
- Manuscript Accepted: 10 MAY 2013
- Manuscript Received: 21 NOV 2012
- National Institute of Diabetes and Digestive and Kidney Diseases. Grant Numbers: 1 R21 DK075857-01A2, U19 AI066313-05
- German Research Foundation (DFG). Grant Number: KO4103/1-1
- American Liver Foundation, the DFG. Grant Numbers: SCHM 2661/1-1, 2661/1-2
- German Federal Ministry of Education and Research (BMBF; PtJ-Bio). Grant Number: 0315883
Additional Supporting Information may be found in the online version of this article.
|hep26526-sup-0001-suppFig1.tif||2850K||Supporting Information Fig. 1|
|hep26526-sup-0002-suppFig2.tif||2658K||Supporting Information Fig. 2|
|hep26526-sup-0003-suppFig3.tif||2716K||Supporting Information Fig. 3|
|hep26526-sup-0004-suppFig4.tif||2873K||Supporting Information Fig. 4|
|hep26526-sup-0005-suppFig5.tif||2986K||Supporting Information Fig. 5|
|hep26526-sup-0006-suppFig6.tif||2819K||Supporting Information Fig. 6|
|hep26526-sup-0007-suppFig7.tif||2715K||Supporting Information Fig. 7|
|hep26526-sup-0008-suppFig8.tif||3611K||Supporting Information Fig. 8|
|hep26526-sup-0009-suppTab1.doc||68K||Suppl. Table 1. Antibodies for Immunostaining and Western blot|
|hep26526-sup-00010-suppTab2.doc||41K||Suppl. Table 2. Sequences of primers and probes used for quantitative RT-PCR|
|hep26526-sup-00011-suppTab3.doc||32K||Suppl. Table 3. Relationship between Shc labeling indices (% positive hepatoma cells/hepatocytes) and clinical parameters associated with hepatocarcinogenesis and liver function|
|hep26526-sup-00012-suppTab4.doc||66K||Suppl. Table 4. Individual sizes and weights of tumors from heat treated HEPG2 cells in nude mice|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.